Cargando…

Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes

BACKGROUND: Myelodysplastic syndromes (MDS) is a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells. Clinically, elevated mature monocyte in bone marrow is often observed, but its clinical value still remains unclear. METHODS: We retrospectively analyzed a cohor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, An, Gao, Panpan, Wu, Ningning, Shi, Cong, Huang, Zhenya, Rong, Chunmeng, Sun, Ye, Sheng, Lixia, Ouyang, Guifang, Mu, Qitian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117396/ https://www.ncbi.nlm.nih.gov/pubmed/33985456 http://dx.doi.org/10.1186/s12885-021-08303-8

Ejemplares similares

Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome
por: Shi, Cong, et al.
Publicado: (2022)

MLL-SEPT5 Fusion Transcript in Myelodysplastic Syndrome Patient With t(11;22)(q23;q11)
por: Zou, Duobing, et al.
Publicado: (2021)

Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes
por: Shi, Cong, et al.
Publicado: (2022)

Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome
por: Chen, Ying, et al.
Publicado: (2023)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score
por: Silzle, Tobias, et al.
Publicado: (2023)

The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes
por: Shi, Cong, et al.
Publicado: (2022)

Prognostic significance of U2AF1 mutations in myelodysplastic syndromes: a meta-analysis
por: Li, Bixia, et al.
Publicado: (2019)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
por: Suh, Koung Jin, et al.
Publicado: (2016)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome
por: Ma, Jiale, et al.
Publicado: (2023)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
por: Pardanani, A, et al.
Publicado: (2012)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia
por: Guo, Shanshan, et al.
Publicado: (2020)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: A case report
por: Rong, Chunmeng, et al.
Publicado: (2021)

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
por: Silzle, Tobias, et al.
Publicado: (2019)

High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies
por: Wan, Ziqi, et al.
Publicado: (2021)

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report
por: Lai, Binbin, et al.
Publicado: (2018)

Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia
por: Ouyang, Guifang, et al.
Publicado: (2019)

Effect of Depth of Electroacupuncture on the IPSS of Patients with Benign Prostatic Hyperplasia
por: Yuan, Hongwei, et al.
Publicado: (2019)

Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023)

Prognostic and therapeutic implications of iron-related cell death pathways in acute myeloid leukemia
por: Li, Tongyu, et al.
Publicado: (2023)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma
por: Yan, Xiao, et al.
Publicado: (2020)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

P725: BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY
por: Schulz, Felicitas, et al.
Publicado: (2023)

Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature
por: Sun, Ye, et al.
Publicado: (2021)

Unusual expansion of CD3+CD56+ natural killer T-like cells in peripheral blood after anticytokine treatment for graft-versus-host disease: A case report
por: Sheng, Lixia, et al.
Publicado: (2018)

Prognostic and immunological characterization of diffuse large B-cell lymphoma evaluated by co-stimulatory molecular-related features
por: Sheng, Lixia, et al.
Publicado: (2023)

An accompaniment to higher mathematics
por: Exner, George R
Publicado: (1996)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
por: Benites, Bruno Deltreggia, et al.
Publicado: (2013)

Bone marrow niches in myelodysplastic syndromes
por: Tosato, Giovanna, et al.
Publicado: (2021)

Monocyte-Derived Macrophages Are Impaired in Myelodysplastic Syndrome
por: Han, Yu, et al.
Publicado: (2016)

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
por: Scheid, C, et al.
Publicado: (2017)

Immunophenotypic changes of monocytes in myelodysplastic syndrome and clinical significance
por: Li, Lijuan, et al.
Publicado: (2022)

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update
por: Jain, Akriti G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nnhbbnsjmv501gsmdo6p8h36bf